Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 17/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142590 | 0.86 | ITK (0.73) | ITKKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL145584 | 0.85 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL29470244 | 0.85 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL4125841 | 0.83 | ITK (1.00) | ITK | |
| SCHEMBL4125079 | 0.80 | ITK (0.68) | ITKCHEK1 | |
| SCHEMBL4120947 | 0.80 | ITK (0.81) | ITKCYP19A1CHEK1 | |
| SCHEMBL5637088 | 0.80 | ITK (0.68) | ITKCHEK1 | |
| SCHEMBL147603 | 0.80 | ITK (0.66) | ITKCHEK1 | |
| SCHEMBL143964 | 0.80 | ITK (0.70) | ITKCHEK1 | |
| SCHEMBL4125482 | 0.79 | ITK (0.81) | ITKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | claimed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | claimed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | claimed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | ITK 1186/4885KDM4E 1737/4885MEN1 3342/4885 |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | KDR, FLT1, FLT4 | ITK 1042/4885KDM4E 961/4885MEN1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.